Zejula OverviewNiraparib (originally MK-4827) is an orally active small molecule PARP inhibitor developed by Tesaro to treat ovarian cancer. On March 27, 2017 , the FDA approved it for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. It is an inhibitor of PARP1 and PARP2. Niraparib was granted fast track designation and Tesaro submitted a new drug app...
Read more Zejula Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Niraparib
Recent Zejula Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Capsule: 100mg